Therapeutic

Continued progress for Vaxxinity against Parkinson’s

Continued progress for Vaxxinity against Parkinson’s

Less than a month since we reported Vaxxinity’s “promising” results in a trial of UB-312, the company has released further encouraging news; new data demonstrates that UB-312 has established “clear target engagement” by slowing seeding of alpha-synuclein (αSyn) in...

Vaccines are the “future” in cancer, says Dr Pravin Kaumaya

Vaccines are the “future” in cancer, says Dr Pravin Kaumaya

During the Congress in April we were pleased to meet Dr Pravin Kaumaya for a conversation about the state of play in the cancer vaccine field. Dr Kaumaya joined us to chair the Cancer and Immunotherapy track, present a session and join a panel. Here we learn more...

UK government and BioNTech join forces on cancer trials

UK government and BioNTech join forces on cancer trials

Following the signing of a memorandum of understanding between the UK government and BioNTech in January 2023, an agreement has been established to provide cancer patients with “improved access” to cancer trials. The partnership will ensure that more patients are able...

Vaxxinity announces positive Parkinson’s trial results

Vaxxinity announces positive Parkinson’s trial results

In June 2023 Vaxxinity announced positive results from Part B of the Phase I clinical trial of UB-312, an investigational vaccine for Parkinson’s disease. The results show that the vaccine was well tolerated and induced anti-alpha-synuclein (aSyn) antibody responses...

Mendus’ vididencel treatment increases cancer-killing cells

Mendus’ vididencel treatment increases cancer-killing cells

In June 2023 at the European Haematology Association event Mendus presented new clinical data from the Phase II ADVANCE II trial in acute myeloid leukaemia (AML) maintenance. The data show that treatment with vididencel led to increased levels of activated,...

Moderna and Merck announce positive DMFS results from trial

Moderna and Merck announce positive DMFS results from trial

In June 2023 Moderna and Merck, who have been collaborating on a Phase IIb study to evaluate mRNA-4157 (V940), announced distant metastasis-free survival (DMFS) results. The trial investigates the combination of KEYTRUDA, Merck’s anti-PD-1 therapy, with an...

Transgene presents positive cancer vaccine data for HPV

Transgene presents positive cancer vaccine data for HPV

French-based biotechnology company Transgene announced in June 2023 that new data confirm that its novel investigational therapeutic cancer vaccine can induce immune responses against HPV16. The results are presented in a poster at the American Society of Clinical...